Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 661 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Speaking with One Cancer Voice for cancer patients in England March 29, 2023 Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age October 26, 2020 Forging Military Partnerships to Empower the Cancer Research Enterprise March 27, 2018 How to Get More Support From Your Oncology Pharmacist During Cancer February 24, 2021 Load more HOT NEWS Lutathera Shows Promise as Part of Initial Therapy for Some Neuroendocrine... Coronavirus y COVID-19: Qué deben saber las personas con cáncer Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... Association of BRCA1 and BRCA2 Pathogenic Variants with Increased Risk of...
